PathologybioRxiv
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
X. Li, J. Eastham, J. M. Giltnane…·H. Koeppen
This paper develops automated tumor immunophenotyping pipelines to predict clinical benefit from anti-PD-L1 therapy in NSCLC and TNBC patients.
DOI 10.1002/path.6274